3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
350
Polycystic Ovary Syndrome
39
Endometrial Neoplasms
22
Neoplasm Metastasis
21
Ovarian Neoplasms
16
Infertility
12
Neoplasms
11
Fallopian Tube Neoplasms
8
Advanced Breast Cancer
8
Triple Negative Breast Neoplasms
7
Carcinoma, Intraductal, Noninfiltrating
7
Carcinoma, Ductal, Breast
7
Breast Neoplasms, Male
7
Recurrence
6
Osteoporosis
6
Carcinoma, Lobular
6
Breast Diseases
6
Breast Carcinoma In Situ
6
Prostatic Neoplasms
5
Leiomyoma
4
Infertility, Female
4
Hereditary Sensory and Autonomic Neuropathies
4
Breast Cancer Metastatic
4
Neoplasms, Hormone-Dependent
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Non-Small-Cell Lung
3
Anovulation
3
Uterine Neoplasms
2
Uterine Cervical Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Interventions
liposomal doxorubicin
1
defactinib
1
Paclitaxel
1
Letrozole
1
Anastrozole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Low Grade Serous Ovarian Cancer
×
Letrozole
×
Clear all
NCT06072781
2026-04-02
RAMP 301
Verastem, Inc.
Phase 3
Recruiting
270 enrolled